Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$46.32
Price-22.52%
-$13.46
1Y
Price
Market Cap
$3.696b
Mid
Price/Earnings 3y Avg5y Avg
23.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+25.5%
EBITDA Margin+20.6%
Net Profit Margin+23.2%
Free Cash Flow Margin+25.5%
EBITDA Margin+20.6%
Net Profit Margin+23.2%
Free Cash Flow MarginRevenue
$561.900m
+4.8%
1y CAGR+14.7%
3y CAGR+16.5%
5y CAGREarnings
$114.483m
+32.6%
1y CAGR+113.3%
3y CAGR+59.1%
5y CAGREPS
$1.40
+31.7%
1y CAGR+108.9%
3y CAGR+56.7%
5y CAGRBook Value
$1.388b
$1.486b
Assets$97.963m
Liabilities$40.107m
DebtDebt to Assets
2.7%
0.3x
Debt to EBITDAFree Cash Flow
$165.455m
+22.3%
1y CAGR+69.0%
3y CAGR+921.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company